Parameter | Nr |
---|---|
A. Patient and tumor characteristics | |
Age (years) Median (range) | 67 (36-87) |
Gender | |
 Male | 24 (56%) |
 Female | 19 (44%) |
Tumor location a | |
 IHCC | 17 (40%) |
 EHCC | 26 (60%) |
Treatment | |
 Primary inoperable | 26 (70%) |
 Recurrent | 8 (22%) |
 Positive margins | 3 (08%) |
Prior therapies | |
 Resection | 12 (32%) |
 Chemotherapy | 6 (16%) |
  Gemcitabine/Oxaliplatin | 1 |
  Gemcitabine | 1 |
  Capecitabin | 1 |
  5-FU | 1 |
Therapies after SBRT | |
 Chemotherapy | 13 (35%) |
 TACE | 1 (03%) |
CA 19-9 (U/ml) Median (IQR) | 149 (20-499) |
Bilirubin (mg/dl) Median (range) | 0.8 (0.5-21) |
GTV Diameter (cm)a Median (IQR) | 4.9 (3.4-8.2) |
PTV Volume (cm3)a Median (IQR) | 124 (60-329) |
B. Treatment characteristics | |
Prescribed dose (Gy)a | |
 Median (IQR) | 45 (38-48) |
 Maximum point dose (Gy)a | |
 Median (IQR) | 51 (44-58) |
 Mean PTV dose (Gy)a | |
 Median (IQR) | 47 (42-51) |
 EQD210 (Gy)a | |
 Median (IQR) | 56 (47-61) |
EQD210 Maximum point dose (Gy) | |
 Median (IQR) | 65 (59-85) |
EQD210 Mean dose (Gy) | |
 Median (IQR) | 63 (53-82) |